Thomas L. Petty Aspen Lung Conference
"Translating Resilience and Pathogenesis
to Personalized Therapy for COPD” Irina
Petrache, M.D., Chair R. William Vandivier, M.D., Chair Moumita Ghosh, Ph.D., Co-Chair June
6-9, 2018 The
Gant Conference Center, Aspen, Colorado
Chronic obstructive pulmonary
disease (COPD) is the 3rd leading cause of death in the United
States and the 4th leading cause of death worldwide. Despite progress, current therapies only
mitigate symptoms and have no clear effect on mortality or the long-term
decline in lung function. Understanding the pathophysiology of COPD, developing
novel treatment strategies, and effectively implementing lung-reparative
therapeutics would be expected to have significant impact on COPD, as well as
other pulmonary diseases. With an
emphasis on the integration of basic, translational and clinical approaches,
the 61st AnnualThomas L. Petty Aspen Lung Conference will focus on a
central question: how can knowledge of resilience or susceptibility to develop COPD be
translated into more effective therapies? To address this central question, we have
organized the program into a series of thematic sessions that will be framed by
a Keynote Address, Clinical Perspective and NHLBI Perspective.
The thematic sessions will focus on (i)
clinical and molecular heterogeneity of COPD,
(ii) COPD as a disease of
accelerated aging, (iii) stem cell
dysfunction and regenerative therapies for COPD, (iv) immune and epithelial cell mechanisms of COPD exacerbations, (v) metabolic and biochemical
mechanisms of COPD pathogenesis, and (vi)
consequences of COPD beyond the obstructed lung. These thematic sessions will
be anchored by state-of-the-art presentations from thought leaders in each
respective area, with ample time dedicated to scientific debate. Finally, the varied scientific themes and
therapeutic strategies emerging during the conference will be reconciled in a
concluding Conference Summary presented by Stephen I. Rennard, M.D., Professor
of Medicine, University of Nebraska and Head, Clinical Discovery Unit,
Abstract deadline is February 14,
2018. For more information, contact: R.
William Vandivier, M.D., c/o Jeanne Cleary, Thomas L. Petty Aspen Lung
Conference, PO Box 1622, Parker, CO 80134
Phone: (303) 358-2797. Fax:
PROGRAM LEARNING OBJECTIVES
We seek to accomplish the following objectives:
provide an international forum for leading basic, translational, and clinical
researchers to exchange ideas regarding fundamental concepts underlying
susceptibility and resistance to develop COPD.
stimulate interactions between the fields of phenotype/endotypes, genomics/epigenetics,
aging, stem cell biology, metabolism and lipid biochemistry with the goal of
identifying emerging, shared interests that may lead to the performance of more
efficient and productive research.
advance our understanding of clinical and molecular COPD phenotypes/endotypes that
predict risk or response in order to quickly translate preclinical findings to more
effective, personalized therapies.
4. To challenge and thereby stimulate the
scientific interests of trainees, attracting a new generation of junior investigators
into the field of COPD pathobiology.
At the conclusion of this conference attendees will
be able to:
1) Discuss the
concept of COPD heterogeneity, and the possibility that unique phenotypes or
endotypes may identify cohorts with common mechanisms of disease and response
2) Appreciate the complex interactions between
genomics/epigenetics, aging, immune/epithelial interactions, metabolism and
lipid biochemistry, and their link to COPD susceptibility and resilience.
3) Incorporate current concepts from stem
cell biology to better understand repair of the injured lung.
4) Understand mechanisms by which pulmonary
vascular disease and lung cancer develop in COPD.
Audience: Local/Regional/National/International Physicians/Clinicians
(adult and pediatric)/Research Physician-Scientists in Pulmonary Sciences,
Critical Care and Sleep Medicine/Primary Care Physicians/General Medicine
AMERICANS WITH DISABILITY ACT STATEMENT
indicate if you have any need for auxiliary aids or special assistance services